A
Alina Dulau-Florea
Researcher at National Institutes of Health
Publications - 34
Citations - 1151
Alina Dulau-Florea is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Bone marrow & Medicine. The author has an hindex of 10, co-authored 29 publications receiving 429 citations. Previous affiliations of Alina Dulau-Florea include Thomas Jefferson University.
Papers
More filters
Journal ArticleDOI
Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease.
David B. Beck,Marcela A. Ferrada,Keith A. Sikora,Amanda K. Ombrello,Jason C. Collins,Wuhong Pei,Nicholas Balanda,Daron L. Ross,Daniela Ospina Cardona,Zhijie Wu,Bhavisha A Patel,Kalpana Manthiram,Emma M. Groarke,Fernanda Gutierrez-Rodrigues,Patrycja Hoffmann,Sofia Rosenzweig,Shuichiro Nakabo,Laura W. Dillon,Christopher S. Hourigan,Wanxia L. Tsai,Sarthak Gupta,Carmelo Carmona-Rivera,Anthony J. Asmar,Lisha Xu,Hirotsugu Oda,Wendy Goodspeed,Karyl S. Barron,Michele Nehrebecky,Anne Jones,Ryan S. Laird,Natalie Deuitch,Dorota Rowczenio,Emily Rominger,Kristina V. Wells,Chyi-Chia Richard Lee,Weixin Wang,Megan Trick,James C. Mullikin,Gustaf Wigerblad,Stephen R. Brooks,Stefania Dell'Orso,Zuoming Deng,Jae Jin Chae,Alina Dulau-Florea,May Christine V. Malicdan,Danica Novacic,Robert A. Colbert,Mariana J. Kaplan,Massimo Gadina,Sinisa Savic,Helen J. Lachmann,Mones Abu-Asab,Benjamin D. Solomon,Kyle Retterer,William A. Gahl,Shawn M. Burgess,Ivona Aksentijevich,Neal S. Young,Katherine R. Calvo,Achim Werner,Daniel L. Kastner,Peter C. Grayson +61 more
TL;DR: Using a genotype-driven approach, this disorder is identified that connects seemingly unrelated adult-onset inflammatory syndromes and is named the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome.
Journal ArticleDOI
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
Nirali N. Shah,Steven L. Highfill,Haneen Shalabi,Bonnie Yates,Jianjian Jin,Pamela L. Wolters,Amanda K. Ombrello,Seth M. Steinberg,Staci Martin,Cindy Delbrook,Leah Hoffman,Lauren Little,Anusha Ponduri,Haiying Qin,Haris Qureshi,Alina Dulau-Florea,Dalia Salem,Hao-Wei Wang,Constance M. Yuan,Maryalice Stetler-Stevenson,Sandhya R. Panch,Minh Tran,Crystal L. Mackall,Crystal L. Mackall,David F. Stroncek,Terry J. Fry,Terry J. Fry +26 more
TL;DR: The remission induction rate supports further development of CD22 CAR T cells as a therapeutic option in patients resistant to CD19-targeted immunotherapy, and novel information on the impact of manufacturing changes on clinical outcomes is provided.
Journal ArticleDOI
Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1
Ifeyinwa Emmanuela Obiorah,Bhavisha A Patel,Emma M. Groarke,Weixin Wang,Megan Trick,Amanda K. Ombrello,Marcela A. Ferrada,Zhijie Wu,Fernanda Gutierrez-Rodrigues,Jennifer Lotter,Lorena Wilson,Patrycja Hoffmann,Daniela Ospina Cardona,Nisha Patel,Alina Dulau-Florea,Daniel L. Kastner,Peter C. Grayson,David B. Beck,Neal S. Young,Katherine R. Calvo +19 more
TL;DR: In this paper, the authors reported clinical hematologic manifestations and unique bone marrow (BM) features in 16 patients with VEXAS, all of whom were male and had a history of severe autoinflammatory and rheumatologic manifestations.
Journal ArticleDOI
Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia
Dai Chihara,Evgeny Arons,Maryalice Stetler-Stevenson,Constance M. Yuan,Hao-Wei Wang,Hong Zhou,Mark Raffeld,Liqiang Xi,Seth M. Steinberg,Julie Feurtado,Lacey R. James,Wyndham H. Wilson,Raul C. Braylan,Katherine R. Calvo,Irina Maric,Alina Dulau-Florea,Robert J. Kreitman,Robert J. Kreitman +17 more
TL;DR: Achieving MRD-free CR of HCL after first-line cladribine is greatly enhanced by concurrent rituximab and less so by delayed ritudine, and long-term follow-up will determine if MRd-free survival leads to less need for additional therapy or cure of H CL.
Journal ArticleDOI
Acquired and germline predisposition to bone marrow failure: Diagnostic features and clinical implications.
TL;DR: Several overlapping acquired marrow failure entities including aplastic anemia, hypoplastic myelodysplasia, and large granular lymphocyte disorders are reviewed; and several bone marrow disorders with germline predisposition are reviewed with a focus on advances related to pathophysiology, diagnosis, and management.